[go: up one dir, main page]

AR002932A1 - Solucion acuosa de interferon - Google Patents

Solucion acuosa de interferon

Info

Publication number
AR002932A1
AR002932A1 ARP960102079A AR10207996A AR002932A1 AR 002932 A1 AR002932 A1 AR 002932A1 AR P960102079 A ARP960102079 A AR P960102079A AR 10207996 A AR10207996 A AR 10207996A AR 002932 A1 AR002932 A1 AR 002932A1
Authority
AR
Argentina
Prior art keywords
interferon solution
aqueous interferon
aqueous
interferon
solution
Prior art date
Application number
ARP960102079A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR002932A1 publication Critical patent/AR002932A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)

Abstract

Una solución acuosa de interferón, que contiene: (a) un interferón alfa;(b) un detergente no iónico; (c) un tampón para ajustar el pH a 4,5 - 5,5;(d) alcohol bencílico; y opcionalmente, (e) un agente isotonizante.
ARP960102079A 1995-04-06 1996-04-03 Solucion acuosa de interferon AR002932A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95105166 1995-04-06

Publications (1)

Publication Number Publication Date
AR002932A1 true AR002932A1 (es) 1998-05-27

Family

ID=8219166

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102079A AR002932A1 (es) 1995-04-06 1996-04-03 Solucion acuosa de interferon

Country Status (31)

Country Link
US (1) US5762923A (es)
EP (1) EP0736303B1 (es)
JP (1) JP2758154B2 (es)
KR (1) KR100212346B1 (es)
CN (1) CN1066065C (es)
AR (1) AR002932A1 (es)
AT (1) ATE183650T1 (es)
AU (1) AU685356B2 (es)
BR (1) BR9601276A (es)
CA (1) CA2172664C (es)
CO (1) CO4750807A1 (es)
CY (1) CY2194B1 (es)
CZ (1) CZ287626B6 (es)
DE (1) DE69603894T2 (es)
DK (1) DK0736303T3 (es)
ES (1) ES2136910T3 (es)
GR (1) GR3031775T3 (es)
HU (1) HU227643B1 (es)
IL (1) IL117752A (es)
MA (1) MA23838A1 (es)
MY (1) MY113594A (es)
NO (1) NO316801B1 (es)
NZ (1) NZ286300A (es)
PE (1) PE38897A1 (es)
PL (1) PL183873B1 (es)
RU (1) RU2113845C1 (es)
SA (1) SA96160728B1 (es)
SG (1) SG52806A1 (es)
TR (1) TR199600287A2 (es)
TW (1) TW426523B (es)
ZA (1) ZA962553B (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6402718B1 (en) 1992-08-17 2002-06-11 Medrad, Inc. Front-loading medical injector and syringe for use therewith
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
NZ336548A (en) * 1996-12-24 2001-09-28 Biogen Inc Stable liquid interferon formulations comprising an amino acid as the stabilising agent
AU754002B2 (en) * 1998-03-26 2002-10-31 Merck Sharp & Dohme Corp. Formulations for protection of peg-interferon alpha conjugates
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
PT1069912E (pt) * 1998-04-03 2007-09-14 Novartis Vaccines & Diagnostic Formulações injectáveis de igf contendo succinato como agente tampão
CN1230198C (zh) 1998-05-15 2005-12-07 先灵公司 给首次接受抗病毒疗法的G慢性丙型肝炎感染患者施用包括利巴韦林和α干扰素的联合疗法
CN1170543C (zh) * 1998-06-08 2004-10-13 弗·哈夫曼-拉罗切有限公司 PEG-IFN-α和三唑核苷在治疗慢性丙型肝炎中的用途
JP4719357B2 (ja) * 1998-07-23 2011-07-06 アレス トレイディング ソシエテ アノニム Ｆｓｈ及びｆｓｈ変異体の製剤、製品及び方法
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PT2158923E (pt) 1998-08-06 2013-06-04 Univ Duke Conjugados de peg-urato oxidase e sua utilização
AU2158000A (en) * 1998-12-22 2000-07-12 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
AR023398A1 (es) 1999-04-08 2002-09-04 Schering Corp Terapia para melanomas
US6923966B2 (en) * 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
KR100399156B1 (ko) * 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
DE60139339D1 (de) 2000-11-07 2009-09-03 Novartis Vaccines & Diagnostic Stabilisierte interferonzusammensetzungen
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
JP2002265383A (ja) * 2001-03-14 2002-09-18 Mitsubishi Pharma Corp インターフェロンα注射用液状製剤
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2002083165A1 (fr) * 2001-04-10 2002-10-24 Sumitomo Pharmaceuticals Co., Ltd. Preparations stables destinees a etre injectees
LT4947B (lt) 2001-09-26 2002-08-26 Biotechnologijos Institutas Interferono alfa farmacinė kompozicija
EP2990417A1 (en) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin insulin fusion protein
JP5000848B2 (ja) 2002-05-21 2012-08-15 第一三共株式会社 グレリン含有医薬組成物
RU2238758C2 (ru) * 2002-07-24 2004-10-27 Закрытое акционерное общество "Вектор-Медика" Водный раствор интерферона-альфа-два человека для инъекций
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
US7741268B2 (en) 2003-04-02 2010-06-22 Ares Trading S.A. Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
HRP20130242T1 (hr) 2003-06-20 2013-04-30 Ares Trading S.A. Smrzavanjem osušene formulacije fsh/lh
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
AR045258A1 (es) * 2003-08-21 2005-10-19 Altana Pharma Ag Un producto farmaceutico para inyeccion
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
KR20070012464A (ko) 2004-05-17 2007-01-25 아레스 트레이딩 에스.아. 하이드로겔 인터페론 제제
CN1993139B (zh) * 2004-06-01 2011-02-16 阿雷斯贸易股份有限公司 稳定的干扰素液体制剂
US7858082B2 (en) * 2004-06-01 2010-12-28 Ares Trading S.A. Method of stabilizing proteins
RU2255729C1 (ru) * 2004-07-26 2005-07-10 Общество С Ограниченной Ответственностью "Фармапарк" Препарат интерферона альфа в форме стабильного водного раствора для инъекций
US7632491B2 (en) 2004-08-12 2009-12-15 Schering Corporation Stable pegylated interferon formulation
CN101022822B (zh) 2004-08-24 2012-06-27 第一三共株式会社 生理学活性肽的液体制剂
RU2270692C1 (ru) * 2004-11-04 2006-02-27 Валентина Васильевна Малиновская Пролонгированный раствор интерферона
ES2538357T3 (es) 2005-04-11 2015-06-19 Crealta Pharmaceuticals Llc Formas variantes de urato oxidasa y uso de las mismas
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
EP1916997B1 (en) * 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
WO2008026044A2 (en) * 2006-08-31 2008-03-06 Wockhardt Research Centre Pharmaceutical compositions of bupropion
KR20150038227A (ko) 2007-01-16 2015-04-08 애브비 인코포레이티드 건선의 치료방법
WO2008145323A1 (en) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
KR101502645B1 (ko) * 2007-09-04 2015-03-13 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ｂ, 이의 제조 방법 및 용도
PT2196475E (pt) * 2007-09-04 2012-09-07 Biosteed Gene Expression Tech Co Ltd Interferão alfa-2a modificado por polietilenoglicol, seu processo de síntese e aplicação
WO2009055343A2 (en) * 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
EA201070773A1 (ru) 2007-12-20 2010-12-30 Мерк Сероно С. А. Составы пэг-интерферона-бета
BRPI0915093A2 (pt) 2008-06-13 2015-10-27 Proyecto Biomedicina Cima Sl conjugados para a administração de compostos biologicamente ativos
US20110195912A1 (en) * 2008-09-17 2011-08-11 Nektar Therapeutics Oligomer-Protease Inhibitor Conjugates
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CN102526758B (zh) * 2012-02-23 2013-02-13 北京三元基因工程有限公司 一种聚乙二醇化干扰素稳定的水溶液
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
CN107073080A (zh) * 2014-09-23 2017-08-18 豪夫迈·罗氏有限公司 包含α‑型干扰素的稳定的不含苄醇的水溶液制剂
JP2019535819A (ja) 2016-11-11 2019-12-12 ホライゾン ファーマ リューマトロジー リミテッド ライアビリティ カンパニーＨｏｒｉｚｏｎ Ｐｈａｒｍａ Ｒｈｅｕｍａｔｏｌｏｇｙ Ｌｌｃ プレドニゾンおよびウリカーゼ分子の併用療法ならびにその使用
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
RU2768656C1 (ru) * 2021-09-10 2022-03-24 Илья Александрович Марков Противовирусное средство в жидкой форме и способ его приготовления
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物
RU2007184C1 (ru) * 1985-11-25 1994-02-15 Научно-исследовательский институт эпидемиологии и микробиологии им.Н.Ф.Гамалеи РАМН Способ лечения сальмонеллезной инфекции
EP0284249A1 (en) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH0651642B2 (ja) * 1988-11-14 1994-07-06 大塚製薬株式会社 インターフェロン経鼻投与用製剤
KR900701310A (ko) * 1988-11-14 1990-12-01 오스카 아끼히꼬 인터페론 경비투여용 제제
CA2033714A1 (en) * 1990-01-25 1991-07-26 Alberto Ferro Pharmaceutical preparations
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid compositions of gamma interferon

Also Published As

Publication number Publication date
PL313655A1 (en) 1996-10-14
KR960037063A (ko) 1996-11-19
CA2172664C (en) 2000-10-03
HUP9600857A2 (en) 1997-08-28
PE38897A1 (es) 1997-10-04
SG52806A1 (en) 1998-09-28
NO961322L (no) 1996-10-07
EP0736303A3 (en) 1997-02-26
US5762923A (en) 1998-06-09
NO316801B1 (no) 2004-05-18
MA23838A1 (fr) 1996-12-31
SA96160728B1 (ar) 2005-05-04
JP2758154B2 (ja) 1998-05-28
DE69603894D1 (de) 1999-09-30
EP0736303B1 (en) 1999-08-25
MY113594A (en) 2002-04-30
PL183873B1 (pl) 2002-07-31
RU2113845C1 (ru) 1998-06-27
CN1066065C (zh) 2001-05-23
NZ286300A (en) 1997-05-26
NO961322D0 (no) 1996-04-01
CY2194B1 (en) 2002-11-08
HUP9600857A3 (en) 1998-01-28
ZA962553B (en) 1996-10-07
KR100212346B1 (ko) 1999-08-02
ATE183650T1 (de) 1999-09-15
CZ287626B6 (en) 2001-01-17
GR3031775T3 (en) 2000-02-29
CO4750807A1 (es) 1999-03-31
HU9600857D0 (en) 1996-05-28
DK0736303T3 (da) 2000-01-10
TW426523B (en) 2001-03-21
IL117752A0 (en) 1996-08-04
CZ99496A3 (en) 1996-10-16
AU685356B2 (en) 1998-01-15
HK1012232A1 (en) 1999-07-30
CA2172664A1 (en) 1996-10-07
ES2136910T3 (es) 1999-12-01
TR199600287A2 (tr) 1997-03-21
DE69603894T2 (de) 2000-04-20
JPH08283176A (ja) 1996-10-29
HU227643B1 (en) 2011-10-28
IL117752A (en) 2000-11-21
CN1141808A (zh) 1997-02-05
AU5044696A (en) 1996-10-17
BR9601276A (pt) 1998-01-13
EP0736303A2 (en) 1996-10-09

Similar Documents

Publication Publication Date Title
AR002932A1 (es) Solucion acuosa de interferon
LU91342I2 (fr) Byetta-exénatide
GT199800126A (es) Terapia de combinacion.
EP0695171A1 (en) GONADOTROPINE CONTAINING FREEZER DRIED DROPS
ES2132547T3 (es) Solucion acuosa concentrada de argatroban.
AR053946A2 (es) Variante de alfa-amilasa de bacillus stearothermophilus original
MX9306499A (es) Composiciones farmaceuticas que contienen una anfetamina.
CO5011037A1 (es) Metodo para mejorar la condicion de la piel de un usuario en el area cubierta por un articulo absorbente
ES2195970T3 (es) L-ribavirina y usos de la misma.
CA2016699A1 (en) Lytic agents and uses thereof
ES2174843T3 (es) Agentes antifungicos peptidicos ciclicos y procedimiento para su preparacion.
AR000714A1 (es) Un metodo de uso de un agente quelante para mejorar la fidelidad de color de telas lavadas y una composicion para uso en dicho metodo.
YU48666B (sh) Mometason furoat monohidrat i postupak za njegovo dobijanje
AR023529A1 (es) Una composicion champu acondicionadora del cabello y un metodo para acondicionar el cabello
ES2175362T3 (es) Agente fitosanitario solido.
EP0843592A4 (en) DEHALOGENATION OF HYDROCARBONS PRESENT IN AQUEOUS COMPOSITIONS
ES2196620T3 (es) Formulacion de liberacion prolongada que contiene venlafaxina.
ES2046852T3 (es) Un procedimiento para preparar un champu.
ES2191417T3 (es) Composicion desinfectante.
AR023006A1 (es) Composicion de champu
BR9610930A (pt) Composição depilatória incluindo uma quantidade funcional de um agente tixoitrópico, e, uso da quantidade funcional de um agente tixotrópico.
ES2132539T3 (es) Composiciones insecticidas sinergicas.
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
MX9303913A (es) Composiciones detergentes liquidas acuosas concentradas que comprenden polivinilpirrolidona y un polimero de liberacion de suciedad basado en tereftalato.
ES2033262T3 (es) Composicion esterilizante a base de glutaraldehido de actividad antibacteriana y antimicotica, en un vehiculo acuoso.